Seeking Alpha
0
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra

Vivus (NASDAQ:VVUS) sales of the anti-obesity pill Qsymia have remained essentially flat for several months. With the exception of holidays, sales have been between 10,000 and 11,300 since the Summer of 2014. That dynamic may get challenged to the negative in the weeks ahead. With the launch of Contrave from Orexigen at a low price point, and with Arena's (NASDAQ:ARNA) Belviq getting a new $75 price, Qsymia may well be the most expensive of the new anti-obesity drugs on the…